Group 1 - electroCore, Inc. announced the appointment of Seth Abrams as VP of Sales effective April 1, 2026, and Michael Fox as Chief Operating Officer effective April 13, 2026 [1] - The Compensation Committee granted 30,000 restricted stock units (RSUs) to Mr. Abrams and 70,000 RSUs to Mr. Fox as part of their employment inducement [1] - The RSUs will vest in three equal parts on the first, second, and third anniversaries of the grant date, contingent on continued employment [1] Group 2 - electroCore, Inc. is a commercial-stage bioelectronic technology company focused on improving health and quality of life through non-invasive bioelectronic technologies [2] - The company's leading products include gammaCore for chronic pain treatment and Quell® for fibromyalgia, utilizing non-invasive neuromodulation technology [2] - electroCore also markets handheld products like Trvuaga and TAC-STIM for general wellness and human performance enhancement [2]

Core Insights - electroCore, Inc. announced that its product gammaCore™ Sapphire (nVNS) has been included in a long-term reimbursement policy by the National Institute for Health and Disability Insurance (RIZIV / INAMI) in Belgium, effective October 1, 2025 [1][2] - The reimbursement policy allows coverage for gammaCore Sapphire to treat patients with cluster headaches, based on strong clinical evidence supporting its efficacy and cost-effectiveness, thus ensuring broader access for Belgian patients [2][3] Company and Product Details - electroCore is a commercial-stage bioelectronic medicine and wellness company focused on improving health through innovative non-invasive technologies, with gammaCore and Quell neurostimulator as its leading products [5] - The company emphasizes the significance of securing long-term reimbursement in Belgium as a major milestone for expanding access to its non-invasive therapies [4] Partnerships and Market Expansion - Silvert Medical, electroCore's distribution partner in Belgium, played a crucial role in securing the reimbursement by leveraging local expertise and provider relationships, and is committed to extending access to gammaCore in neighboring countries [3][4] - The partnership with Silvert Medical is highlighted as a key factor in bringing gammaCore to patients in Belgium and enhancing the company's market presence in Europe [4]

Company Overview - electroCore, Inc. is a commercial-stage bioelectronic technology company focused on improving health and quality of life through innovative non-invasive bioelectronic technologies [2] - The company's leading prescription products include gammaCore, a non-invasive vagus nerve stimulation (nVNS) device, and Quell neurostimulator, both aimed at treating chronic pain syndromes [2] - Additionally, electroCore offers Truvaga products, which are handheld nVNS devices designed for personal use to promote general wellness and human performance [2] Upcoming Financial Results - electroCore will report its financial results for the second quarter ended June 30, 2025, after the market closes on August 6, 2025 [1] - Management will host a webinar at 4:30 PM EDT on the same day to review the financial results and address investor questions [1] - Investors can access the webinar through a provided registration link and dial-in details [1]